Valuation: Cocrystal Pharma, Inc.

Market Cap 19.17M 17.17M 15.79M 14.31M 26.74M 1.82B 27.24M 188M 75.59M 957M 71.93M 70.4M 3.02B P/E 2026 *
-1.37x
P/E 2027 * -2.09x
Enterprise Value 19.17M 17.17M 15.79M 14.31M 26.74M 1.82B 27.24M 188M 75.59M 957M 71.93M 70.4M 3.02B EV / Sales 2026 *
0.17x
EV / Sales 2027 * -
Free-Float
34.29%
Yield 2026 *
-
Yield 2027 * -
1 day+1.53%
1 week+4.74%
Current month-13.48%
1 month-13.48%
3 months+14.67%
6 months-30.42%
Current year+1.63%
1 week 0.94
Extreme 0.94
1.01
1 month 0.91
Extreme 0.91
1.18
Current year 0.76
Extreme 0.76
2.03
1 year 0.76
Extreme 0.76
2.03
3 years 0.76
Extreme 0.76
3.26
5 years 0.76
Extreme 0.76
11.95
10 years 0.76
Extreme 0.76
180
Manager TitleAgeSince
Chief Executive Officer 65 03/06/2026
Chief Executive Officer 59 27/05/2021
Chief Executive Officer 66 27/05/2021
Director TitleAgeSince
Director/Board Member 89 02/01/2014
Chairman 79 27/05/2021
Director/Board Member 65 02/01/2014
Date Insider Type Main position Quantity % Market Cap. Importance
5/8/26 Buy

Director

10,000 0.0725%
3/8/26 Buy

Director

75,000 0.5440%
3/6/26 Free

Chief Executive Officer

235,000 1.7044%
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%+4.74%-8.72%-38.76% 19.17M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.46%+7.26%+42.20%+181.81% 39.44B
Weighted average by Cap. +0.18%+5.44%+48.50%+186.12%

Financials

2026 *2027 *
Net sales 110M 98.52M 90.62M 82.11M 153M 10.44B 156M 1.08B 434M 5.49B 413M 404M 17.33B -
Net income -11.66M -10.44M -9.6M -8.7M -16.26M -1.11B -16.57M -115M -45.97M -582M -43.75M -42.82M -1.84B -10.75M -9.63M -8.86M -8.02M -15M -1.02B -15.28M -106M -42.39M -537M -40.34M -39.49M -1.69B
Net Debt - -
Projected Income Statement - Annual - Cocrystal Pharma, Inc.
Logo Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Employees
10
Date Price Change Volume
30/10/26 US$0.9950 +1.53% 62,764
29/10/26 US$0.9800 -1.01% 14,735
28/10/26 US$0.9900 +0.93% 32,735
27/10/26 US$0.9809 +0.93% 17,481
26/10/26 US$0.9719 +2.31% 21,940
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cocrystal Pharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.9950USD
Average target price
8.000USD
Spread / Average Target
+704.02%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cocrystal Pharma, Inc.
  1. Stock Market
  2. Stocks
  3. COCP Stock